Demo Account   Live Account  

Newsroom

  • Share:

Medtronic dips after FDA panel votes against use of hypertension treatment device

Investing.com -- Shares in Medtronic PLC (NYSE:MDT) fell in early trading on Thursday after a regulatory panel in the U.S. voted against recommending the use of its blood pressure treatment device.

The independent expert panel of the Food and Drug Administration (FDA) said that the risks of utilizing the company's Symplicity Spyral Renal Denervation System outweighed its benefits. Minnesota-based Medtronic's device aims to help patients with hypertension who cannot be aided by drugs.

But its benefits were subject to deep debate, with six members of the FDA's Circulatory System Devices Panel each voting for and against it. Only a vote by the panel's chairperson broke the deadlock.

Seven of the 13 members voted in favor of the procedure's effectiveness, while all the members voted that it was safe to use.

The FDA is not obligated to follow the panel's decision, although it rarely chooses not to listen to its advice.

In a statement, Jason Weidman, senior vice president of Medtronic's Coronary and Renal Denervation business,  said that it will continue to collaborate with the FDA on developing a new option.

Begin trading today! Create an account by completing our form

Privacy Notice

At One Financial Markets we are committed to safeguarding your privacy.

Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.

Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.

Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.

By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Back to top

English Footer

Office network

One Financial Markets is the trading name of Axi Financial Services (UK) Ltd, a company registered in England with company number 6050593. Axi Financial Services (UK) Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201)

The information on this site is not directed at residents of the United States, Belgium, Poland or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

www.onefinancialmarkets.com is owned and operated by Axi Financial Services (UK) Ltd.

Award winning broker
We have been presented with a number of awards that recognise the quality of our service and dedication to our clients :

Best FSA Regulated Broker
Saudi Money Expo

Best Education Product
Saudi Money Expo

Best Broker - Online Trading
IAIR Awards

Best Institutional Broker
Saudi Money Expo

Best FX Services Broker
CN Forex

Top International
FX Broker 2015
Saudi Money Expo

Broker of the Year
Online Trading – Middle East
IAIR Awards

Best Forex
Customer Service 2018
JFEX Awards

We accept the following payment methods:

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.